Protagonist Therapeutics (PTGX) Change in Acquisitions & Divestments (2016 - 2026)

Protagonist Therapeutics has reported Change in Acquisitions & Divestments for 11 years, with the latest figure at $156.7 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 2137.48% year-over-year to $156.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $641.5 million (up 148.08% YoY) and the FY2025 annual result came in at $491.8 million, up 52.0% from the prior year.
• Change in Acquisitions & Divestments climbed to $156.7 million in Q1 2026 per PTGX's latest filing, from $153.2 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $331.6 million in Q3 2025 and troughed at $7.0 million in Q1 2025.
• A 5-year average of $89.5 million and a median of $76.6 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2025 and 2026: Change in Acquisitions & Divestments sank 90.27% in 2025, then jumped 2137.48% in 2026.
• Over 5 years, Change in Acquisitions & Divestments stood at $84.6 million in 2022, then plunged by 56.62% to $36.7 million in 2023, then surged by 188.81% to $106.0 million in 2024, then surged by 44.57% to $153.2 million in 2025, then rose by 2.26% to $156.7 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $156.7 million, $153.2 million, and $331.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.